12:57PM ET 6/24/2022 MT NewswiresCytomX Therapeutics (CTMX) shares gained more than 1% in Friday afternoon trading after BMO Capital started coverage of the company with an outperform...
4:55AM ET 6/24/2022 MT NewswiresCytomX Therapeutics (CTMX) has an average rating of buy and price targets ranging from $6 to $16, according to analysts polled by Capital IQ. (MT Newswires...
5:25AM ET 5/31/2022 MT NewswiresCytomX Therapeutics (CTMX) has an average rating of buy and price targets ranging from $6 to $16, according to analysts polled by Capital IQ. (MT Newswires...
9:37AM ET 5/26/2022 MT NewswiresCytomX Therapeutics (CTMX) said Thursday it has dosed the first patient in a phase 1 dose-escalation study of CX-904, a drug candidate to fight cancer...